Context: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and castrate testosterone levels, with no radiological findings of metastatic disease on computed...
Positron emission tomography/computed tomography (PET/CT) has recently emerged as a promising diagnostic imaging platform for prostate cancer. Several radiolabelled tracers have demonstrated efficacy...
Purpose: Aggressive variant prostate cancer (AVPC) is a non-androgen receptor-driven form of disease that arises in men who have failed standard-of-care therapies. Therapeutic options for AVPC are limited, and the development of...
Lantheus Holdings, Inc. has announced that the FDA has approved Pylarify, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis or recurrence of prostate cancer.
Since its introduction in the diagnostic pathway of prostate cancer management, prostate-specific membrane antigen (PSMA)-ligand positron-emission tomography (PET) has demonstrated great potential.
This study sought to evaluate whether there were differences in survival between patients with prostate cancer – stratified into high risk and very high risk groups – who were treated with radiotherapy and androgen deprivation.
The FDA has approved Axumin (fluciclovine (18F)), a radioactive diagnostic agent for injection from Blue Earth Diagnostics Ltd. Axumin is...
Purpose of review: The aim of this article is to review the role of prostate radiotherapy in the multimodal management of newly diagnosed metastatic hormone naïve prostate cancer.
Venous thromboembolism (VTE) is a major healthcare problem due to its high incidence, significant mortality rate from pulmonary embolism, high recurrence rate and morbidity from long-term complications.
Lantheus Holdings, Inc. announced that the FDA has approved Pylarify, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis or recurrence of prostate cancer.